Diseases
Every condition and disease as data, in the vocabulary your systems already use
Coverage
- Every condition on a label or in a trial. 141,000+ conditions in all.
- Mapped to the standard ontologies: UMLS, SNOMED CT, MedDRA, MeSH, and ICD-10.
- Built into a hierarchy. Synonyms and alternate names resolve to one condition, which sits under its parents and above its subtypes.
- Every use and exclusion: 21,800+ indications and 9,900+ contraindications, each with its own region, route, and age group; 1,300+ off-label, and 6,000+ conditions flagged rare.
Where it connects
Condition record
Duchenne Muscular Dystrophy (DMD)
DBCOND0040032
Drugs
Every drug with an indication recorded on the condition
nameAtaluren
drugbank_idDB05016
approval_statusapproved, withdrawn
modalitySmall molecule
kindmanagement_of
countryEU
off_labelfalse
+8 more drugs
Targets
The targets of the drugs indicated for it
biodb_nameDystrophin
uniprot_idP11532
ttd_strength_of_evidencePhase 2; Phase 2/3; Approved
ot_score0.8429
combined_score1.5929
+1,796 more proteins
Clinical trials
Trials with the condition on their record, and what phase each is at
NCT05126758
NCT05524883
NCT05540860
NCT05558813
NCT05689164
NCT05933057
NCT05938023
+244 more
NCT05933057.statusrecruiting
NCT05689164.statusterminated
NCT05558813.statuswithdrawn
NCT05558813.phases[]
Companies
Sponsors of those trials, resolved to the parent company
Via a registered trial
trialNCT05689164
sponsor.title (as filed)Pfizer
agency_classindustry
sponsor_company.name (resolved)Pfizer
+71 more industry sponsors
Via a preclinical program
programDBPRG00151626
raw_phaseIND-enabling
company.name (resolved)Dyne Therapeutics
+205 more programs
Zoom in
| drug | drug_drugbank_id | kind | country | route | dose_form | age_groups |
|---|---|---|---|---|---|---|
| Delandistrogene moxeparvovec | DB16802 | treatment_of | US | Intravenous | Kit | pediatric |
| Givinostat | DB12645 | treatment_of | US | Oral | Suspension | [] |
| Casimersen | DB14984 | treatment_of | US | Intravenous | Injection | [] |
| Eteplirsen | DB06014 | management_of | US | Intravenous | Injection | [] |
| Vamorolone | DB15114 | management_of | EU | Oral | Suspension | [] |
| Ataluren | DB05016 | management_of | EU | [] | [] | [] |
+4 more indications
| identifier_type | identifier | title |
|---|---|---|
| MedDRA | llt/10013801 | Duchenne muscular dystrophy |
| MedDRA | pt/10059117 | Becker's muscular dystrophy |
| MeSH | t/T811507 | Muscular Dystrophy, Duchenne Type |
| MeSH | c/M0583499 | Duchenne and Becker Muscular Dystrophy |
| SNOMED CT | c/76670001 | null |
| UMLS | cui/C0013264 | null |
| ICD-10 | c/G71.01 | null |
+39 more codes
| drug | drug_drugbank_id | relationship | region | route |
|---|---|---|---|---|
| Tegaserod | DB01079 | patient_condition | US | Oral |
| Cabazitaxel | DB06772 | patient_condition | US | Intravenous |
| Abiraterone | DB05812 | patient_condition | EU | Oral |
| Diclofenac | DB00586 | patient_condition | Canada | Topical |
| Estriol | DB04573 | patient_condition | Italy | Vaginal |
| Treprostinil | DB00374 | patient_condition_associated_with | US | Oral |
+82 more contraindications
| generic_name | orphan_designation | designation_status | designation_date | marketing_approval_date |
|---|---|---|---|---|
| delandistrogene moxeparvovec-rokl | Treatment of Duchenne Muscular Dystrophy | designated_approved | 2018-06-21 | 2024-06-20 |
| vamorolone | Treatment of Duchenne muscular dystrophy | designated_approved | 2011-12-02 | 2023-10-26 |
| golodirsen | Treatment of Duchenne muscular dystrophy (DMD) | designated_approved | 2018-05-22 | 2019-12-12 |
| Brogidirsen | Treatment of Duchenne muscular dystrophy | designated | 2023-07-31 | null |
| Elamipretide HCl | Treatment of Duchenne Muscular Dystrophy | designated | 2022-05-10 | null |
| (-)-epi-gallocatechin-3-gallate | Treatment of Duchenne Muscular Dystrophy | designated_withdrawn | 2024-03-21 | null |
+50 more designations
| condition | condition_drugbank_id | drug | kind | country |
|---|---|---|---|---|
| Primary Amyloidosis | DBCOND0040057 | Cyclophosphamide | used_in_combination_to_manage | United Kingdom |
| Primary Amyloidosis | DBCOND0040057 | Dexamethasone | used_in_combination_to_manage | United Kingdom |
| Norwegian scabies | DBCOND0025572 | Ivermectin | used_in_combination_to_treat | null |
| Rhinopharyngitis | DBCOND0052141 | Pseudoephedrine | used_in_combination_for_symptomatic_treatment_of | Turkey |
| Ocular Hypertension | DBCOND0074237 | Pilocarpine | used_in_combination_to_treat | null |
+1,344 more off-label indications
Questions it answers
- Which approved drugs could be repositioned into this indication? Landscape and whitespace analysis
- How crowded is this indication, from preclinical to approved? Landscape and whitespace analysis
- What's the orphan precedent here before we commit? Target diligence
All figures pulled as of November 2026.